UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $118.28 and traded as high as $133.68. UCB shares last traded at $133.68, with a volume of 270 shares trading hands.
UCB Trading Up 4.0 %
The company’s fifty day moving average is $118.28 and its two-hundred day moving average is $94.42.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Stories
- Five stocks we like better than UCB
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend Payout Ratio Calculator
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
